SFH
Nov 17-19
Marseille, France
Riksstamman
Dec 1 - 3
Gothenburg, Sweden
SFVTT
Dec 8 - 10
Reims, France
INTERCEPT Plasma Receives Swiss Approval
The Swiss regulatory body, Swissmedic, has approved the use of plasma components treated with INTERCEPT. This provides the Swiss blood centers with the option to treat both platelets and plasma with INTERCEPT, taking advantage of the natural synergy between the two processes. To date, INTERCEPT is the only technology approved in Switzerland for pathogen inactivation treatment of platelets and plasma.
Read press release
Replay of the Cerus AABB 2010 Workshop
Chaired by Emma Castro, MD, this presentation by Louis Katz, MD and William Reed, MD, explores the challenges faced by healthcare decision makers and blood centers in times of broad public concern about a new emerging pathogen – XMRV. The possible role that pathogen inactivation (PI) can play as a defense against emerging pathogens is discussed.
Watch replay
The Swiss regulatory body, Swissmedic, has approved the use of plasma components treated with INTERCEPT. This provides the Swiss blood centers with the option to treat both platelets and plasma with INTERCEPT, taking advantage of the natural synergy between the two processes. To date, INTERCEPT is the only technology approved in Switzerland for pathogen inactivation treatment of platelets and plasma.
Read press release
Replay of the Cerus AABB 2010 Workshop
Chaired by Emma Castro, MD, this presentation by Louis Katz, MD and William Reed, MD, explores the challenges faced by healthcare decision makers and blood centers in times of broad public concern about a new emerging pathogen – XMRV. The possible role that pathogen inactivation (PI) can play as a defense against emerging pathogens is discussed.
Watch replay
Domestic Malaria Case Reported in Spain
An autochthonous case of Plasmodium vivax malaria was diagnosed in the Aragon region of Spain where the Anopheles atroparvusis vector is endemic. This is the first case since 1961. Emerging and re-emerging vector-borne diseases continue to impact Europe. Vigilance among transfusion the medicine community is warranted.
Read article
An autochthonous case of Plasmodium vivax malaria was diagnosed in the Aragon region of Spain where the Anopheles atroparvusis vector is endemic. This is the first case since 1961. Emerging and re-emerging vector-borne diseases continue to impact Europe. Vigilance among transfusion the medicine community is warranted.
Read article
CSL to Work with Cerus to Commercialize INTERCEPT in Australia and New Zealand
CSL Limited, Biotherapies division and Cerus has agreed to distribute the INTERCEPT Platelet System in Australia and New Zealand. Cerus expects that should the blood services plan to adopt the system, they will need first to obtain regulatory approval for use of INTERCEPT-treated platelets.
Read press release
CSL Limited, Biotherapies division and Cerus has agreed to distribute the INTERCEPT Platelet System in Australia and New Zealand. Cerus expects that should the blood services plan to adopt the system, they will need first to obtain regulatory approval for use of INTERCEPT-treated platelets.
Read press release
UK Prohibits ME/CFS Blood Donations ![]()
New safety guidelines from the UK’s Blood Services will permanently defer sufferers of myalgic encephalomyelitis (ME) or chronic fatigue syndrome (CFS) from donating blood. Though the intent is to prevent causing harm to the donor, some see this as an effective means of preventing the transfusion-transmission of XMRV, a virus controversially linked to several disease states including CFS.
Read news release
Watch video: ME Debate in House of Lords
New safety guidelines from the UK’s Blood Services will permanently defer sufferers of myalgic encephalomyelitis (ME) or chronic fatigue syndrome (CFS) from donating blood. Though the intent is to prevent causing harm to the donor, some see this as an effective means of preventing the transfusion-transmission of XMRV, a virus controversially linked to several disease states including CFS.Read news release
Watch video: ME Debate in House of Lords
 |
||
|
Detecting Retroviral Sequences in Chronic Fatigue Syndrome I Singh Viruses 2010, 2(11), 2404-2408 Read more  Protection Against TA-GVHD in Platelet Transfusion by Pathogen Inactivation with the INTERCEPT Blood System™ - Gamma Irradiation is NOT the Only Answer L Lin, L Corash and JC Osselaer Haematologica 2010;95(extra):86-93 Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet-A light: evaluation of an indicator label H Isola, D Brandner, E Stahl, L Corash and JP Cazenave Vox Sang 2010 Nov;99(4):402 [Epub ahead of print] Read more Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period JP Cazenave, H Isola, C Waller, et al Transfusion 2010 Sep. [Epub ahead of print] Read more In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System) P Chavarin, F Cognasse, C Argaud, M Vidal, C De Putter, F Boussoulade, C Ripaud, S Acquart, L Lin, O Garraud. Vox Sang 2010 Aug 24. [Epub ahead of print] Read more |
|
